Nangle LA, Xu Z, Siefker D, Burkart C, Chong YE, Zhai L, Geng Y, Polizzi C, Guy L, Eide L, Tong Y, Klopp-Savino S, Ferrer M, Rauch K, Wang A, Hamel K, Crampton S, Paz S, Chiang K, Do M, Burman L, Lee D, Zhang M, Ogilvie K, King D, Adams RA, Schimmel P.
Science Translational Medicine (2025)
Anti-Fibrotic Activity Observed Across Preclinical Models of Pulmonary and Renal Fibrosis for a Potential Therapeutic Based on Asp-tRNA Synthetase
Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, 2024
A Newly Evolved Domain of Asp-tRNA Synthetase Interacts with Latent Transforming Growth Factor Beta Binding Protein 1 (LTBP-1) to Induce Myofibroblast Apoptosis
Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, 2024
Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis
Obi ON, Baughman RP, Crouser ED, Julian, MW, Locke, LW, Chandrasekaran A, Ramesh P, Kinnersley N, Niranjan V, Culver DA, Sporn PHS
European Respiratory Journal (2024)
Efzofitimod is an Immunomodulator of Myeloid Cell Function and Novel Therapeutic Candidate for Interstitial Lung Diseases
American Thoracic Society, 2024
Alanyl-tRNA synthetase fragment binds to FGFR4 and induces morphological changes and downstream signaling in liver cells with functional similarities to FGF2
Gordon Research Conference: Fibroblast Growth Factors in Development and Disease, 2024
Efzofitimod Promotes Macrophages with Anti-inflammatory Profile via Neuropilin-2 Receptor
Keystone Symposia: Myeloid Cell Diversity, 2024
Demonstration of an Isoform-Specific Anti-inflammatory Role for Neuropilin-2 Through a Novel Interaction with the Chemokine Ligand 21
Keystone Symposia: Myeloid Cell Diversity, 2024
Efzofitimod, a First-in-Class NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
American College of Rheumatology, 2023
Exposure-Response Analyses of Efzofitimod in Patients With Pulmonary Sarcoidosis
Frontiers in Pharmacology, 2023